Evaluation of the serum testosterone to prostate-specific antigen ratio as a predictor of prostate cancer risk

BJU International

Volumn 105, Issue 4, 2010, Pages 481-484

  Morote, Juan ^a   Planas, Jacques ^a   Ramirez, Cristobal ^a   Gómez, Esther ^a   Raventós, Carles X ^a   Placer, José ^a   Catalán, Roberto ^b   De Torres, Inés M ^b  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Prediction; Prostate cancer; PSA; Ratio; Serum testosterone

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER RISK; DIAGNOSTIC ACCURACY; DIGITAL RECTAL EXAMINATION; GROUPS BY AGE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; ORGAN SIZE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; TESTOSTERONE BLOOD LEVEL; TRANSRECTAL ULTRASONOGRAPHY;

AGED; EPIDEMIOLOGIC METHODS; HUMANS; HYPOGONADISM; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TESTOSTERONE;

EID: 76149117790     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2009.08761.x     Document Type: Article

References (18)

1. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002. Cancer Incidence, Mortality and Prevalence Worldwide, Version 2.0. Lyon, France : IARC Press, 2004
2. Bostwick DG, Burke HB, Djakiew D et al. Human prostate cancer risk factors. Cancer 2004 101 : 2371 2490
3. Morote J, Raventós CX, Lorente JÁ et al. Comparison of percent free psa and psa density as methods to enhace psa specificity in early prostate cancer detection in men with normal rectal examination and PSA between 4.1 and 10 ng/ml. J Urol 1997 158 : 502 504
4. Morote J, Trilla E, Esquena S et al. The percentage of free prostatic-specific antigen is also useful in men with normal digital rectal examination and serum prostatic-specific antigen between 4.1 and 10 ng/ml. Eur Urol 2002 42 : 333 338
5. Ribeiro M, Ruff P, Falkson G. Low serum testosterone and a younger age predict for a poor outcome in metastatic prostate cancer. Am J Clin Oncol 1997 20 : 605 608
6. Hoffman M, DeWolf WC, Morgentaler A. Is low serum free testosterone a marker for high grade prostate cancer? J Urol 2000 163 : 824 827
7. Schatzl G, Madersbacher S, Thurridl T et al. High-grade prostate cancer is associated with low serum testosterone levels. Prostate 2001 47 : 52 8
8. Massengill JC, Sun L, Moul JW et al. Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy. J Urol 2003 169 : 1670 1675
9. Teloken C, Da Ros CT, Caraver F et al. Low serum testosterone levels are associated with positive surgical margins in radical retropubic prostatectomy: hypogonadism represents bad prognosis in prostate cancer. J Urol 2005 174 : 2178 2180
10. San Francisco IF, Regan MM, Dewolf WC, Olumi AF. Low age adjusted free testosterone levels correlate with poorly differentiated prostate cancer. J Urol 2006 175 : 1341 1346
11. Morgentaler A. Testosterone and prostate cancer: an historical perspective on a modern myth. Eur Urol 2006 50 : 935 939
12. Tubaro A. Testosterone and prostate cancer. Eur Urol 2007 51 : 293 295
13. Yano M, Imamoto T, Suzuki H et al. The clinical potential of pretreatment serum testosterone level to improve the efficiency of prostate cancer screening. Eur Urol 2007 51 : 375 380
14. Karamanolakis D, Lambou T, Bogdanos J et al. Serum testosterone. A potentially adjunct screening test for the assessment of the risk of prostate cancer among men with modestly elevated PSA values (greater than or 3.0 and less than 10.0 ng/ml). Anticancer Res 2006 26 : 3159 3166
15. Rhoden EL, Riedner CH, Morgentaler A. The ratio of serum testosterone-to-prostate specific antigen predicts prostate cancer in hypogonadal men. J Urol 2008 179 : 1741 1745
16. Remzi M, Fong YK, Dobrovits M et al. The Vienna nomogram: validation of a novel biopsy strategy defining the optimal number of cores based on patient age and total prostate, J. Urol 2005 174 : 1256 1261
17. Roddam AW, Allen NE, Appleby P, the Endogenous Hormones and Prostate Cancer Collaborative Group. Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. J Natl Cancer Inst 2008 100 : 170 183
18. Morote J, Ramirez C, Gómez E et al. The relationship between total and free serum testosterone and the risk of prostate cancer and tumour aggressiveness. BJU Int 2009 104 : 486 489